Controversial Neurologist to Lead NIH Child Health Unit

The National Institutes of Health (NIH) has appointed John Gaitanis, MD, a pediatric neurologist, to lead its Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD). Gaitanis is known for holding controversial views regarding the causes and treatment of autism spectrum disorder (ASD). His appointment has drawn attention and raised questions within the scientific and medical communities due to his past statements and research perspectives. The NICHD is a primary federal agency for research on child, maternal, and reproductive health, focusing on understanding human development, improving the health of children and adolescents, and promoting the health and well-being of families. The institute supports a broad range of research, from basic science to clinical and epidemiological studies, aiming to prevent and treat diseases and conditions affecting children.

In a separate development reported by Science, a cohort study has identified an association between the age at which individuals experience menopause and their brain volume trajectory. This research suggests that the timing of menopause may have long-term implications for brain health and structural changes over time. The study analyzed data from a cohort of individuals, tracking their brain volume and correlating it with their menopausal status. Understanding these associations is crucial for developing strategies to support cognitive health in aging populations, particularly women who undergo menopause. Further research is likely needed to elucidate the underlying biological mechanisms and potential interventions.

Additionally, a trial involving fathers and the drug valproate has been halted. Valproate, an anticonvulsant and mood-stabilizing medication, is known to carry significant risks, particularly for fetal development when taken by pregnant individuals. While its teratogenic effects are well-documented in relation to maternal use, research into paternal exposure and its potential impact on offspring is less extensive but growing. The halting of this trial suggests potential concerns related to its design, execution, or preliminary findings that warrant further investigation or reconsideration. The specific reasons for the halt were not detailed in the provided text, but such actions in clinical trials typically stem from safety issues, ethical considerations, or a lack of efficacy.